Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,012,444

« Back to Dashboard

Summary for Patent: 4,012,444

Title: 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
Abstract:Compounds of the formula: ##STR1## and physiologically acceptable acid addition salts thereof, in which R.sup.1 is A. an arylalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms and the aryl portion of which may be substituted by one or more alkoxy groups or hydroxy groups; or B. an aryloxyalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms, and the aryloxy portion of which is substituted with one or more alkoxy or hydroxy groups. These compounds have a blocking action on both .alpha.- and .beta.-adrenergic receptors. Processes for the production of these compounds and pharmaceutical compositions containing them are also provided.
Inventor(s): Lunts; Lawrence Henry Charles (London, EN), Collin; David Trevor (London, EN)
Assignee: Allen & Hanburys Limited (London, EN)
Application Number:05/420,547
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 4,012,444

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
34379/69Jul 8, 1969

International Patent Family for Patent: 4,012,444

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria280996► Subscribe
Austria300763► Subscribe
Belgium704037► Subscribe
Belgium752892► Subscribe
Canada932734► Subscribe
Canada983524► Subscribe
Switzerland492676► Subscribe
Switzerland582647► Subscribe
Switzerland583170► Subscribe
Switzerland592051► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Federal Trade Commission
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus